206
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Improved and ‘Nitrosamines Free’ Process for the Preparation of an α4β2 Neuronal Nicotinic Acetylcholine Receptor Agonist-Varenicline Tartrate

, ORCID Icon, , & ORCID Icon
Pages 5299-5309 | Received 04 Sep 2021, Accepted 29 Jun 2022, Published online: 23 Jul 2022
 

Abstract

An improvised and efficient approach for synthesis of α4β2 nicotinic acetylcholine receptor subtype agonist, Varenicline tartrate (1) free from the ‘N-nitrosamines’ has been described. The approach involves an improved process for a key intermediate (7,8-dinitro-4,5-dihydro-1H-1,5-methanobenzo[d] azepin-3(2H)-yl)-2,2,2-trifluoro ethanone (7) free from potential genotoxic impurities. Compound 7 is converted into Varenicline base 10 in a single pot process with improved overall yield and quality. Further, Varenicline base 10 is converted into Varenicline tartrate (1) by acid addition salt which provides in quantitative yield. Our improved process consists of technical innovations/improvements which eliminate the probability for the formation of critical impurities such as dinitro nitroso impurity 2, diamino nitroso impurity 3 and varenicline nitroso impurity 4 and other genotoxic impurities such as mono nitro impurity 11 and meta dinitro impurity 12 in the final drug substance and provides ‘Nitrosamines free’ varenicline tartrate (1) with good quality and yield.

Graphical abstract

Acknowledgements

One of the authors (Ramesh Goura) thanks to the Maithri Drugs Pvt. Ltd for giving opportunity to pursue Ph.D. Our sincere thanks to Dr. Ch. Nagaraju for providing infrastructural facilities to carry out the research work, and also be indebted to Dr. Anil Kumar Muthyala, Dr. Vijayalaxmi Chapala and Udaya Sagar Gavini for their continuous guidance and support.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Notes

1 MDPL-TC Communication No. 001.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.